NRX Pharmaceuticals (NRXP) Total Non-Current Liabilities (2021 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Total Non-Current Liabilities of $17.0 million for Q1 2026, down 25.97% year-over-year from $22.9 million in Q1 2025, and up 2.19% quarter-over-quarter from $16.6 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Total Non-Current Liabilities for 5 consecutive years, with $17.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 25.97% year-over-year to $17.0 million; the TTM figure through Mar 2026 stood at $17.0 million (down 25.97% YoY), while the FY2025 annual figure was $16.6 million, down 21.88% from the prior year.
- Total Non-Current Liabilities rose to $17.0 million in Q1 2026 per NRXP's latest filing, from $16.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $24.9 million in Q3 2025 and bottomed at $16.6 million in Q4 2025.
- Historically, Total Non-Current Liabilities has averaged $21.2 million across 4 years, with a median of $21.4 million in 2024.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities grew 16.41% — and 2026, when it declined 25.97%.
- NRX Pharmaceuticals' Total Non-Current Liabilities stood at $19.0 million in 2023, then climbed by 11.58% to $21.2 million in 2024, then fell by 21.88% to $16.6 million in 2025, then increased by 2.19% to $17.0 million in 2026.
- Business Quant data shows NRXP's Total Non-Current Liabilities at $17.0 million in Q1 2026, $16.6 million in Q4 2025, and $24.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 15.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.95 Mn |
| Dec 31, 2025 | 16.59 Mn |
| Sep 30, 2025 | 24.89 Mn |
| Jun 30, 2025 | 24.19 Mn |
| Mar 31, 2025 | 22.90 Mn |
| Dec 31, 2024 | 21.24 Mn |
| Sep 30, 2024 | 21.38 Mn |
| Jun 30, 2024 | 23.65 Mn |
| Dec 31, 2023 | 19.03 Mn |
| Dec 31, 2021 | 13.02 Mn |
| Sep 30, 2021 | 37.87 Mn |
| Jun 30, 2021 | 59.41 Mn |